Erythroid differentiation and modulation of c-myc expression induced by antineoplastic drugs in the human leukemic cell line K562

G. P. Tonini, D. Radzioch, A. Gronberg, M. Clayton, E. Blasi, G. Benetton, L. Varesio

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The human leukemia cell line K562 expresses constitutively high levels of c-myc mRNA and can be induced to differentiate along the erythroid lineage. Treatment of K562 cells with the antineoplastic drugs 1-β-D-arabinofuranosylcytosine and daunomycin causes differentiation into hemoglobin-producing cells. The differentiation process is associated with an early block of cellular proliferation occurring during the first 24 h of treatment. RNA synthesis is progressively reduced to 20 to 30% of the control levels after 3 days of exposure to the drugs. Dot and Northern blot analyses were performed to evaluate the levels of c-myc or globin mRNA during the differentiation of K562. Daunomycin and 1-β-D-arabinofuranosylcytosine, despite their distinct chemical nature, induced similar modulation of mRNA levels. Globin mRNA did not change during the first 24 h of culture and began to increase after 48 h of treatment with drugs, reflecting the kinetic of appearance of hemoglobin-producing cells. In contrast, a transient decrease of c-myc mRNA was observed after the first 24 h of drug treatment, followed by a return to normal levels of c-myc mRNA after 48 h of treatment. Thus, the expression of c-myc mRNA in K562 did not reflect their proliferative activity nor their stage of differentiation. We speculate that the transient down-regulation of c-myc mRNA may be an initial event in the erythroid differentiation of K562.

Original languageEnglish
Pages (from-to)4544-4547
Number of pages4
JournalCancer Research
Volume47
Issue number17
Publication statusPublished - 1987

Fingerprint

Antineoplastic Agents
Cell Line
Messenger RNA
Daunorubicin
Globins
Cytarabine
Hemoglobins
K562 Cells
Pharmaceutical Preparations
Northern Blotting
Leukemia
Down-Regulation
Pharmacokinetics
Cell Proliferation
RNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tonini, G. P., Radzioch, D., Gronberg, A., Clayton, M., Blasi, E., Benetton, G., & Varesio, L. (1987). Erythroid differentiation and modulation of c-myc expression induced by antineoplastic drugs in the human leukemic cell line K562. Cancer Research, 47(17), 4544-4547.

Erythroid differentiation and modulation of c-myc expression induced by antineoplastic drugs in the human leukemic cell line K562. / Tonini, G. P.; Radzioch, D.; Gronberg, A.; Clayton, M.; Blasi, E.; Benetton, G.; Varesio, L.

In: Cancer Research, Vol. 47, No. 17, 1987, p. 4544-4547.

Research output: Contribution to journalArticle

Tonini, GP, Radzioch, D, Gronberg, A, Clayton, M, Blasi, E, Benetton, G & Varesio, L 1987, 'Erythroid differentiation and modulation of c-myc expression induced by antineoplastic drugs in the human leukemic cell line K562', Cancer Research, vol. 47, no. 17, pp. 4544-4547.
Tonini GP, Radzioch D, Gronberg A, Clayton M, Blasi E, Benetton G et al. Erythroid differentiation and modulation of c-myc expression induced by antineoplastic drugs in the human leukemic cell line K562. Cancer Research. 1987;47(17):4544-4547.
Tonini, G. P. ; Radzioch, D. ; Gronberg, A. ; Clayton, M. ; Blasi, E. ; Benetton, G. ; Varesio, L. / Erythroid differentiation and modulation of c-myc expression induced by antineoplastic drugs in the human leukemic cell line K562. In: Cancer Research. 1987 ; Vol. 47, No. 17. pp. 4544-4547.
@article{6abbfd469c57422e9388d296912df0e4,
title = "Erythroid differentiation and modulation of c-myc expression induced by antineoplastic drugs in the human leukemic cell line K562",
abstract = "The human leukemia cell line K562 expresses constitutively high levels of c-myc mRNA and can be induced to differentiate along the erythroid lineage. Treatment of K562 cells with the antineoplastic drugs 1-β-D-arabinofuranosylcytosine and daunomycin causes differentiation into hemoglobin-producing cells. The differentiation process is associated with an early block of cellular proliferation occurring during the first 24 h of treatment. RNA synthesis is progressively reduced to 20 to 30{\%} of the control levels after 3 days of exposure to the drugs. Dot and Northern blot analyses were performed to evaluate the levels of c-myc or globin mRNA during the differentiation of K562. Daunomycin and 1-β-D-arabinofuranosylcytosine, despite their distinct chemical nature, induced similar modulation of mRNA levels. Globin mRNA did not change during the first 24 h of culture and began to increase after 48 h of treatment with drugs, reflecting the kinetic of appearance of hemoglobin-producing cells. In contrast, a transient decrease of c-myc mRNA was observed after the first 24 h of drug treatment, followed by a return to normal levels of c-myc mRNA after 48 h of treatment. Thus, the expression of c-myc mRNA in K562 did not reflect their proliferative activity nor their stage of differentiation. We speculate that the transient down-regulation of c-myc mRNA may be an initial event in the erythroid differentiation of K562.",
author = "Tonini, {G. P.} and D. Radzioch and A. Gronberg and M. Clayton and E. Blasi and G. Benetton and L. Varesio",
year = "1987",
language = "English",
volume = "47",
pages = "4544--4547",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Erythroid differentiation and modulation of c-myc expression induced by antineoplastic drugs in the human leukemic cell line K562

AU - Tonini, G. P.

AU - Radzioch, D.

AU - Gronberg, A.

AU - Clayton, M.

AU - Blasi, E.

AU - Benetton, G.

AU - Varesio, L.

PY - 1987

Y1 - 1987

N2 - The human leukemia cell line K562 expresses constitutively high levels of c-myc mRNA and can be induced to differentiate along the erythroid lineage. Treatment of K562 cells with the antineoplastic drugs 1-β-D-arabinofuranosylcytosine and daunomycin causes differentiation into hemoglobin-producing cells. The differentiation process is associated with an early block of cellular proliferation occurring during the first 24 h of treatment. RNA synthesis is progressively reduced to 20 to 30% of the control levels after 3 days of exposure to the drugs. Dot and Northern blot analyses were performed to evaluate the levels of c-myc or globin mRNA during the differentiation of K562. Daunomycin and 1-β-D-arabinofuranosylcytosine, despite their distinct chemical nature, induced similar modulation of mRNA levels. Globin mRNA did not change during the first 24 h of culture and began to increase after 48 h of treatment with drugs, reflecting the kinetic of appearance of hemoglobin-producing cells. In contrast, a transient decrease of c-myc mRNA was observed after the first 24 h of drug treatment, followed by a return to normal levels of c-myc mRNA after 48 h of treatment. Thus, the expression of c-myc mRNA in K562 did not reflect their proliferative activity nor their stage of differentiation. We speculate that the transient down-regulation of c-myc mRNA may be an initial event in the erythroid differentiation of K562.

AB - The human leukemia cell line K562 expresses constitutively high levels of c-myc mRNA and can be induced to differentiate along the erythroid lineage. Treatment of K562 cells with the antineoplastic drugs 1-β-D-arabinofuranosylcytosine and daunomycin causes differentiation into hemoglobin-producing cells. The differentiation process is associated with an early block of cellular proliferation occurring during the first 24 h of treatment. RNA synthesis is progressively reduced to 20 to 30% of the control levels after 3 days of exposure to the drugs. Dot and Northern blot analyses were performed to evaluate the levels of c-myc or globin mRNA during the differentiation of K562. Daunomycin and 1-β-D-arabinofuranosylcytosine, despite their distinct chemical nature, induced similar modulation of mRNA levels. Globin mRNA did not change during the first 24 h of culture and began to increase after 48 h of treatment with drugs, reflecting the kinetic of appearance of hemoglobin-producing cells. In contrast, a transient decrease of c-myc mRNA was observed after the first 24 h of drug treatment, followed by a return to normal levels of c-myc mRNA after 48 h of treatment. Thus, the expression of c-myc mRNA in K562 did not reflect their proliferative activity nor their stage of differentiation. We speculate that the transient down-regulation of c-myc mRNA may be an initial event in the erythroid differentiation of K562.

UR - http://www.scopus.com/inward/record.url?scp=0023227661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023227661&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 4544

EP - 4547

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 17

ER -